19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017...
20:23 , Dec 22, 2017 |  BC Week In Review  |  Company News

Boehringer, Autifony in deal for potassium channel modulators

Autifony Therapeutics Ltd. (Stevenage, U.K.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire its potassium channel Kv3.1 (KCNC1)/KCNC2 modulator program. Autifony will receive €25 million ($29.5 million) up front and is eligible...
22:29 , Dec 18, 2017 |  BC Extra  |  Company News

Boehringer, Autifony in deal for potassium channel modulators

Autifony Therapeutics Ltd. (Stevenage, U.K.) granted Boehringer Ingelheim GmbH (Ingelheim, Germany) an exclusive option to acquire its potassium channel Kv3.1 (KCNC1)/KCNC2 modulator program. Autifony will receive €25 million ($29.5 million) up front and is eligible...
15:01 , Jun 2, 2017 |  BC Week In Review  |  Clinical News

Autifony begins Phase Ib of AUT00206 in schizophrenia

Autifony Therapeutics Ltd. (Stevenage, U.K.) began a double-blind, placebo-controlled, U.K. Phase Ib trial of twice-daily 800 mg oral AUT00206 for 4 weeks as adjunctive therapy in about 24 recently diagnosed schizophrenic patients. The trial is...
21:32 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

AUT00206: Additional Ph Ia data

Data from 32 evaluable healthy volunteers in a double-blind, placebo-controlled, U.K. Phase Ia trial showed that oral AUT00206 significantly reduced Mismatch Negativity (MMN) latency at 8 hours post-dose on day 1. According to the company,...
01:21 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

AUT00206: Ph Ib started

Autifony began a double-blind, 4-way crossover, U.K. Phase Ib trial of oral AUT00206 in about 16 healthy male volunteers. Subjects will receive 800 or 2,000 mg AUT00206 or placebo during a ketamine challenge or placebo...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

AUT00206: Phase I data

A double-blind, placebo-controlled, U.K. Phase I trial in over 60 healthy volunteers showed that single ascending doses and once-daily doses of oral AUT00206 for up to 28 days given in fed and fasted states were...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

AUT00206: Phase I started

Autifony began a double-blind, placebo-controlled, dose-escalation, U.K. Phase I trial to evaluate oral AUT00206 in healthy men. In the first part, up to 24 volunteers will receive up to 5 single doses either after fasting...